Immunity to pathogens often requires both B celldependent humoral immune responses and T celldependent cellular immune responses, which cooperate to clear infectious organisms. CD4 + T cells clearly participate in humoral immune responses, by providing help to B cells, and can enhance cellular immunity by producing cytokines; however the converse possibility -that B cells participate in both types of immune response -is not widely accepted. Some early studies of B cell-deficient mice indicated that the absence of B cells adversely affected both CD4 + T cell [1] [2] [3] [4] and CD8 + T cell responses 5, 6 . However, other studies showed that B cells were dispensable for the generation and maintenance of antigen-specific T cell responses [7] [8] [9] [10] . Given that many of the developmental and architectural defects observed in B cell-deficient mice are likely to influence T cell responses, it has been difficult to unambiguously assign a role for B cells in regulating cellular immune responses to either pathogens or autoantigens.
Immunity to pathogens often requires both B celldependent humoral immune responses and T celldependent cellular immune responses, which cooperate to clear infectious organisms. CD4 + T cells clearly participate in humoral immune responses, by providing help to B cells, and can enhance cellular immunity by producing cytokines; however the converse possibility -that B cells participate in both types of immune response -is not widely accepted. Some early studies of B cell-deficient mice indicated that the absence of B cells adversely affected both CD4 + T cell [1] [2] [3] [4] and CD8 + T cell responses 5, 6 . However, other studies showed that B cells were dispensable for the generation and maintenance of antigen-specific T cell responses [7] [8] [9] [10] . These conflicting results were further confused by data showing that mice lacking B cells during embryonic development have many immunological abnormalities, including defects in Peyer's patch organogenesis 11 , the loss of both follicular dendritic cells 12, 13 and gp38-expressing stromal cells in the spleen 14 , alterations in splenic dendritic cell homeo stasis 15 and decreased T cell numbers in the thymus 16 and spleen 14 . Given that many of the developmental and architectural defects observed in B cell-deficient mice are likely to influence T cell responses, it has been difficult to unambiguously assign a role for B cells in regulating cellular immune responses to either pathogens or autoantigens.
The role of B cells in cellular immune responses is now receiving renewed interest owing to the emergence of clinical data showing that B cell depletion is an effective therapy for several T cell-mediated autoimmune diseases, such as multiple sclerosis 17 , type 1 diabetes 18 , rheumatoid arthritis 19 and others 20, 21 . Indeed, studies in both humans and mice show that the clinical efficacy of B celldepletion therapy does not necessarily correlate with changes in the levels of circulating autoantibody, suggesting that B cells may contribute to autoimmunity independently of autoantibody production 22, 23 . Importantly, transient B cell-depletion studies, which distinguish the role of B cells during development from their roles during the course of an immune response, have provided convincing evidence that B cells do indeed regulate T cell-mediated immune responses. Furthermore, as described below, newly developed mouse models, in which B cells are present but cannot secrete antibody, show that B cells can regulate T cell-mediated immune responses through antibody-independent mechanisms.
In this Review, we focus on new data from patients and mouse models showing that B cells modulate CD4 + T cell responses. Specifically, we discuss the roles that B cells have in regulating the development, proliferation and maintenance of CD4 + effector T cells and memory T cells, and we discuss the data that suggest B cells can also modulate the number of regulatory T cells. We review experiments showing that recently described 'effector' and 'regulatory' B cell subsets modulate the function of T cells by presenting antigen, providing co-stimulation and producing cytokines that direct the proliferation and effector functions of responding T cells. Collectively, these data show that B cells are not simply the passive recipients of T cell help, but actively participate in cellular immune responses by directing the magnitude and quality of the T cell response to foreign and self antigens. complement-dependent cytotoxicity mechanisms 24, 25 . Rituximab treatment depletes naive and memory B cells from peripheral blood 26 . However, it is less effective in depleting tissue-resident marginal zone and germinal centre B cells 24, 27 and does not affect long-lived plasma cells, which do not express CD20 (Ref. 26) .
Given the relative effectiveness of B cell depletion by rituximab, this drug has been tested in various diseases. It is approved to treat non-Hodgkin's lymphoma and to treat patients with rheumatoid arthritis who have disease that is refractory to tumour necrosis factor (TNF)-targeted therapy. Rituximab is also being evaluated for the treatment of other autoimmune diseases, including systemic lupus erythematosus (Sle), type 1 diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, mixed cryoglobulinaemia vasculitis (MCV), multiple sclerosis and others 20 . To date, most clinical studies have focused on measuring the extent of B cell depletion and clinical correlates of disease remission. Interestingly, the titres of some autoantibodies declined following B cell depletion but others did not 22, 23 , suggesting that some autoantibody responses are continuously initiated by cohorts of CD20-expressing B cells whereas others are probably maintained by long-lived CD20-negative plasma cells. Regardless of this, many studies found that B cell depletion was clinically effective even in patients that did not show decreased autoantibody titres 22, 23 , indicating that B cells must also contribute to pathology by mechanisms other than autoantibody production.
The effective treatment of T cell-mediated autoimmune diseases by B cell depletion has prompted investigators to examine whether rituximab treatment can alter the subset composition, activation or function of T cells (TABLeS 1, 2). In rituximab-treated patients with pemphigus vulgaris 28 , B cell depletion therapy did not change the proportion of total T cells in the peripheral blood of these patients, but led to a substantial reduction in the frequency of desmoglein-specific (autoreactive) T cells producing interferon-γ (IFNγ) or interleukin-4 (Il-4) 28 . By contrast, rituximab treatment did not affect the number of IFNγ-producing tetanus toxoid-specific T cells 28 . Patients who remained in complete remission for more than one year exhibited the greatest decline in desmoglein-reactive T cells, whereas autoreactive T cells re-emerged in patients who relapsed 28 . Interestingly, the titres of desmoglein-specific autoantibody correlated with the frequency of autoreactive T cells: rituximabtreated patients with fewer desmoglein-reactive T cells also had lower titres of desmoglein-specific antibody, whereas relapsed patients, whose autoreactive T cell numbers increased, also showed increased levels of desmoglein-specific autoantibodies 28 . These data suggest that B cells contribute to pemphigus vulgaris both directly, through autoantibody production, and indirectly, through regulation of autoreactive T cells.
Similar results were observed in patients with idiopathic thrombocytopenic purpura 29 . although autoantibodies do contribute to the pathogenesis of idiopathic thrombocytopenic purpura, patients often present with monoclonal or pauciclonal repertoires of T cells, which are preferentially skewed towards the production of T helper 1 (T H 1)-type cytokines such as IFNγ 30 . In addition, T cells from patients with idiopathic thrombocytopenic purpura express higher levels of the antiapoptotic protein B cell lymphoma 2 (BCl-2) and lower levels of the pro-apoptotic protein BCl-2-associated X protein (BaX), and they are more resistant to apoptosis than T cells from healthy controls 30 . each of these T cell abnormalities was reversed in patients with idio pathic thrombocytopenic purpura who responded positively to B cell depletion therapy but was unaffected in nonresponders 29 , suggesting that the efficacy of the B cell depletion therapy was associated with changes in T cell repertoire and function. Thus, in patients with pemphigus vulgaris and idiopathic thrombocytopenic purpura, as well as in other human and mouse autoimmune diseases, B cells seem to enhance autoreactive T cell responses (TABLeS 1, 2).
Increased regulatory T cell development. T cells were also phenotypically altered in rituximab-treated patients with Sle. In one study, rituximab treatment lowered the number of CD40 ligand (CD40l)-expressing CD4 + T cells in the peripheral blood of patients with Sle, but the treatment did not alter the number of CD4 + T cells expressing other activation markers, such as Hla-DR, CD69 or CD25 (Ref. 31) . In a follow up study, the investigators showed that rituximab treatment decreased CD40L mRNa expression by T cells from responder patients 32 . Interestingly, investigators analysing two separate cohorts of patients with Sle reported that the frequency of CD4 + CD25 hi T cells in peripheral blood was substantially increased after B cell depletion 33, 34 , and these T cells also expressed forkhead box P3 (FoXP3) 34 . Furthermore, the proportion of CD4 + T cells spontaneously producing Il-10 or transforming growth factor-β (TGFβ) was increased in the rituximab-responsive patients 33 . Increased levels of mRNas associated with regulatory T cells, such as CD25, FOXP3, cytotoxic T lymphocyte antigen 4 (CTLA4) and glucocorticoid induced TNF-receptor related protein (GITR), were observed in the rituximab-responsive patients 32 . Notably, FOXP3 mRNa levels remained low in patients with Sle who did not respond to rituximab therapy and declined to baseline levels in patients who relapsed 32 . Together, these data are consistent with the suggestion that successful rituximab treatment not only curtails effector T cell responses but also promotes the expansion of regulatory T cell populations.
In support of this hypothesis, rituximab-treated patients with MCV also showed changes in effector and regulatory T cell populations. Patients with MCV normally present with increased systemic levels of T H 1-type cytokines and greater numbers of both activated T cells and activated, clonally expanded memory B cells 35 . after rituximab treatment, the numbers of both B cells and T cells decreased in a subset of patients with MCV 36 . The clinical efficacy of the B cell depletion correlated best with lower systemic levels of IFNγ and Il-12 and a decrease in the size of the clonally expanded B cell population 36 . In addition, investigators observed a notable increase in the frequency of CD4
+ regulatory T cells in rituximab-responsive MCV patients but not in non-responder patients or patients who relapsed in less than one year 36 . These data suggest that elimination of the clonal (and presumably autoreactive) B cells decreases inflammation and favours the development or proliferation of regulatory T cells.
Similar increases in regulatory T cells were reported in a B cell-depleted autoimmune mouse model. early rituximab treatment (before the onset of clinical disease) of non-obese diabetic (NoD) mice expressing a human CD20 transgene 27 led to decreased insulitis and delayed the onset of diabetes 32 . Moreover, rituximab treatment after the onset of hyperglycaemia, combined with therapeutic administration of insulin, led to long-term remission in 36% of the animals and ultimately ameliorated the requirement for daily insulin injections 37 . Mice that were B cell depleted before disease onset had increased numbers of FoXP3 + T cells, and CD4 + T cells from these animals suppressed diabetes in adoptive transfer experiments 37 . In addition, the B cells that repopulated rituximab-treated animals could suppress diabetes development when transferred with autoreactive T cells into NoD-severe combined immunodeficient (SCID) hosts 37 . These results suggest that depletion of the pathogenic B cell population led to the establishment of both regulatory B cell and regulatory T cell populations and indicated that at least some B cells can suppress autoimmune disease.
an increase in the number of regulatory T cells was also observed in NoD mice treated with B cell maturation antigen (BCMa)-Fc, which blocks B cellactivating factor (BaFF)-mediated and a proliferation-inducing ligand (aPRIl)-mediated survival signals for B cells 38 . B cell depletion with BCMa-Fc in 9-week-old NoD mice (after the onset of insulitis) prevented hyperglycaemia and islet destruction, even though this treatment did not effectively deplete all of the B cells in the pancreas and diabetogenic T cells were still present and could cause disease when transferred into NoD-SCID recipients 38 . Therefore the remaining lymphocytes seemed to be controlled in the BCMa-Fc treated animals. Indeed, T cells from the spleen and pancreatic lymph nodes of BCMaFc-treated mice were less activated as measured by decreased CD40l expression and decreased systemic levels of Il-17 (Ref. 38 + regulatory T cells in the pancreatic lymph nodes and islets increased in NoD mice following treatment with CD22-specific monoclonal antibodies to deplete B cells 39 . Similar to the results of the rituximab experiments described earlier 37 , B cells that repopulated the CD22-specific antibody-treated mice prevented the development of diabetes when transferred with diabetogenic T cells into NoD-SCID hosts 39 . Transcriptome analysis of these 'protective' B cells revealed fundamental changes in gene expression with almost 200 genes downregulated in the newly emerging B cells compared with B cells from normoglycaemic 10-week-old NoD mice 39 . The B cells that repopulated the hosts were also less effective at presenting antigen to T cells and in inducing inflammatory cytokine production by T cells . In fact, T cells and T cell subsets were present in typical numbers in the thymus and secondary lymphoid tissues of B cell-depleted mice 40 . In addition, the phenotypic and transcriptional profiles of the peripheral T cells in B cell-depleted mice were identical to those of T cells from non-depleted mice 40 . Furthermore, the T cells from B cell-depleted mice responded normally to polyclonal stimuli such as treatment with combined CD3-and CD28-specific antibodies 40 . These data suggest that the effects of B cell depletion on T cell function probably arise owing to B cell interactions with T cells responding to antigen. 51 . In these experiments, the number of lCMVspecific IFNγ-producing CD4 + T cells was reduced by 60% in B cell-deficient mice on day 8 after primary infection and was dramatically reduced (by 95%) on day 70 post-infection 51 . lCMV-specific memory CD4 + T cells were normal in mice in which B cells could not produce specific antibody 51 , which indicates that although B cells were required to maintain CD4 + T cell memory, antibody-antigen complexes were not needed. Interestingly, in B cell-deficient mice, lCMV-specific memory CD4 + T cells disappeared early after primary infection (within 1 month), during the contraction phase of the T cell response 51 , suggesting that B cells have a role in the establishment or early maintenance of lCMV-specific memory CD4 + T cells. B cells were also required for the reactivation of memory T cells after herpes simplex virus (HSV) reinfection 52 . In this model, mice were vaccinated with attenuated HSV and then challenged with virulent HSV-2. Protection depended on IFNγ-producing CD4 + T cells that were reactivated by MHC class II-expressing, uninfected antigen-presenting cells 52 . When vaccinated mice were depleted of B cells alone, or depleted of either dendritic cells or macrophages, they were still protected after reinfection 52 . However, T H 1 cell-mediated protection against HSV was completely abrogated when both B cells and dendritic cells were depleted before the challenge infection 52 . Therefore B cells, in combination with dendritic cells, maximize the memory CD4 + T cell recall response to this virus.
Suppression of CD4
+ T cells. In addition to activating T cells, B cells may also modulate regulatory T cell development, proliferation and survival. In support of this possibility, one recent study showed that culturing CD19
+ human B cells with CD4 + CD25 + alloreactive T cells, plus Il-2 and CD28-specific antibody, induced a 40-fold expansion of regulatory T cells 53 . The expanded T cells expressed FoXP3 and were highly suppressive in in vitro assays 53 . Interestingly, the antigen specificity of the regulatory T cells was determined by the stimulating B cells 53 . In a second study, CD40l-activated B cells were used to induce regulatory T cells 54 . Co-culture of CD40l-stimulated human B cells with naive CD4 + CD45Ra + CD45Ro -CD25 -T cells resulted in the expansion of a population of CD4 hi T cells that also expressed CD25, FoXP3, CTla4 and GITR 54 . These T cells suppressed the proliferation of T cells responding to the original target alloantigens presented by the B cells 54 . Importantly, no exogenous stimuli were added to the co-cultures, indicating that the CD40l-activated B cells, which expressed high levels of MHC class II, CD80 and CD86 and secreted substantial amounts of Il-2 (Ref. 54) , provided all of the necessary signals to induce regulatory T cell development.
B cells were also required for regulatory T celldependent tolerance induction 55 . ovalbumin-specific regulatory T cells can be induced in normal mice by transferring naive ovalbumin-specific transgenic CD4 + T cells into recipient hosts and then repeatedly administering ovalbumin coupled to the cholera toxin B subunit through the sublingual, nasal or oral routes 56 . This tolerance protocol was less effective when the naive T cells were transferred into B cell-deficient hosts, resulting in the development of fewer FoXP3 + regulatory T cells and poorly suppressed ovalbumin-specific effector T cell responses 55 . However, transfer of both naive B cells and naive ovalbumin-specific CD4 + T cells to the B celldeficient hosts rescued their ability to generate suppressive ovalbumin-specific FoXP3 + regulatory T cells 55 . Moreover, B cells from the ovalbumin-tolerized mice expressed higher levels of Il10 mRNa than B cells from mice treated with phosphate-buffered saline 55 , and transfer of the B cells from orally tolerized mice to new hosts suppressed naive CD4 + T cell responses following vaccination with ovalbumin and adjuvant 55 . Together, these results suggest that a subset of Il-10-producing B cells, activated in response to a tolerogenic antigen, promoted the development of regulatory T cells.
all of these studies, when taken together, show that B cells participate in inducing primary T cell proliferation and in generating, maintaining and reactivating memory T H 1 and T H 2 T cells through antigen-specific, but antibody-independent, mechanisms. The data also show that B cells can modulate regulatory T cells. Therefore these data predict that B cells have dual and potentially opposing roles in T cell responses. Recently, this hypothesis was elegantly tested in a mouse model of experimental autoimmune encephalomyelitis (eae) induced by immunization with myelin oligodendrocyte glycoprotein (MoG) peptide. The severity of eae disease was found to be higher in mice that had been depleted of B cells 7 days before immunization with MoG peptide than in mice that were not B cell depleted 57 . Moreover, the number of autoreactive, cytokine-producing T cells in the central nervous system increased in mice depleted of B cells before immunization 57 . 59 and that alloantibodies, particularly in presensitized (already immune) individuals, contribute to the cellular rejection process 60 . Treatment of sensitized individuals with rituximab seems to decrease alloantibody titres and, when combined with other therapies (such as corticosteroids and plasmapheresis), can be highly effective in suppressing T cell-mediated rejection of the organ following transplant 58 . By contrast, depletion of B cells from non-sensitized (naive) individuals seems to greatly enhance acute T cell-mediated rejection 61 , suggesting that the depletion of a regulatory population of B cells can enhance destructive T cell-mediated alloresponses. Therefore the experimental and clinical data suggest that there must be several functionally distinct populations of regulatory and effector B cells that can modulate T cell responses (fIG. 2) .
Functions of effector and regulatory B cells
Antigen presentation and co-stimulation. Many of the studies described above show that B cells modulate effector, memory and regulatory T cell responses by antibody-independent mechanisms. one way by which B cells can modulate T cell responses independently of antibody is by presenting antigen to T cells. although it is often assumed that antigen-presenting dendritic cells are not only necessary but also sufficient for CD4 + T cell activation, proliferation and differentiation 62 , it is clear that antigen-presenting B cells can be important for the proliferation and differentiation of T cells 1, 42, 44, 45, 50, [63] [64] [65] [66] and that B cells are particularly effective antigen-presenting cells when antigen is limiting [67] [68] [69] . Thus, B cells may become increasingly relevant as antigen-presenting cells when antigen load is low. Consistent with this suggestion, a recent study using B cell-depleted mice showed that B cells are essential for CD4 + T cell responses when mice are immunized with limiting amounts of antigen but are dispensable when larger quantities of antigen are used 40 . In addition to antigen presentation by B cells, evidence suggests that B cells that express co-stimulatory molecules can modulate T cell responses 43, [70] [71] [72] . For example, experiments using mice in which B cells, but not other antigen-presenting cells, cannot express CD80 and CD86 (B cell co-stimulatory molecule-deficient mice) showed that expression of these co-stimulatory molecules by B cells was required for the activation and/or the proliferation of autoreactive CD4 + T cells in a mouse model of arthritis 72 . Indeed, CD4 + T cells from B cell co-stimulatory molecule-deficient mice with arthritis proliferated less in vitro following restimulation with arthritis-inducing cartilage autoantigens than T cells from wild-type mice with arthritis 72 . Moreover, T cells from B cell co-stimulatory moleculedeficient mice with arthritis were less effective at inducing severe arthritis when transferred into SCID recipient animals 72 . although these experiments did not address whether B cell-dependent co-stimulation is required for memory CD4 + T cell responses to the arthritis-inducing autoantigens, B cells that lacked CD80 and CD86 were far less effective than wild-type B cells in activating CD4 + memory T cells in vitro 72 . This suggests that B cells are likely to provide co-stimulatory signals to T cells during both primary and secondary responses to antigen. In follow-up experiments, the same group reported that transiently depleting B cells 4 days after a secondary challenge with cartilage autoantigens decreased the number of IFNγ-and Il-17-producing autoantigen-specific CD4 + T cells 73 . In addition, T cells from B cell-depleted mice could not transfer disease to SCID recipients 73 . Therefore antigen-presenting, co-stimulatory moleculeexpressing B cells can activate and expand effector and memory T cell populations.
Cytokine production. In addition to presenting antigen and providing co-stimulation to T cells, B cells secrete cytokines and chemokines either constitutively or in response to antigen, Toll-like receptor (TlR) ligands, T cells or combinations of these stimuli 74, 75 . although it has been known for decades that B cells can make cytokines 76 , the concept that the B cell-produced cytokines are involved in modulating CD4 + T cell functions is relatively new 74, 75 . However, increasing evidence suggests that cytokine-producing B cells are involved in humoral and cellular immune responses. For example, one group recently showed that FoXP3 + regulatory T cells proliferate in co-cultures containing splenic B cells and T cells stimulated by CD3-specific antibody; they also showed that the proliferation of regulatory T cells depends on the production of TGFβ3 by the B cells 77 . Similarly, TGFβ-expressing B cells, induced in vivo in a model of local inhal ation tolerance, were sufficient to promote the conversion of CD4 + CD25 -T cells into FoXP3 + regulatory T cells 78 . Therefore, cytokines made by B cells can either directly suppress T cell responses or can enhance the development and maintenance of regulatory T cells which subsequently suppress effector T cell functions.
B cells can be functionally subdivided based on their cytokine profile. Indeed, previous work from our group has revealed that B cells primed by T cells as well as antigen and/or TlR ligands in the presence of T H 1-type cytokines secrete IFNγ and the p40 subunit of Il-12 (in mice) or IFNγ and the p70 subunit of Il-12 (in humans). These B cells, which we have termed B effector 1 cells ('Be1' cells), do not secrete substantial amounts of Il-4, Il-13 or Il-2 but can secrete Il-10, TNF and Il-6 (RefS 79,80 [83] [84] [85] [86] .
Regulatory Il-10-producing B cells suppress CD4 + T cell responses and can prevent the induction of autoimmune disease in several mouse models [83] [84] [85] . Il-10-producing B cells are found in both B-1 and B-2 lineage B cells, and recent data suggest that there are several phenotypically distinct populations of Il-10-producing B cells that can function in a regulatory capacity [83] [84] [85] [86] . experiments characterizing one population of Once the ratio of regulatory/effector cells is biased towards the effector response and the cytokine milieu is dominated by pro-inflammatory cytokines, the regulatory loop is repressed and the B cell-T cell antigen-driven feedforward loop is established. When B cells are depleted early, before the immune response is initiated, the regulatory B and T cell loop is not established, leading to an unchecked effector T cell response. By contrast, when effector and regulatory B cells are depleted later in the immune response, then effector T cell expansion and inflammatory cytokine production are curtailed owing to interruption of the effector B cell-T cell feedforward loop. Regulatory B cells are also eliminated by the depletion therapy, but the remaining regulatory T cells, which are no longer exposed to the high level of inflammatory cytokines, can expand and more efficiently suppress the remaining autoreactive effector T cells. 
Follicular B cell
A recirculating, mature B cell that populates the follicles of the spleen and lymph nodes.
regulatory B cells showed that B cells expressing markers of transitional T2 B cells produce Il-10 and can prevent the development of autoimmunity 87, 88 . other studies suggested that follicular B cells 89 or B cells expressing high levels of CD1d 90, 91 can also produce Il-10 and function as regulatory B cells. In the most recent study, a CD5 + CD1d hi Il-10-producing regulatory B cell population was assessed in more detail 82 . Transfer of these Il-10-producing B cells into B cell-deficient or B cell-depleted mice blocked the CD4 + T cell-dependent inflammatory response in a contact hypersensitivity model 82 . Importantly, the suppressive function of CD5 + CD1d hi B cells was antigen dependent, as regulatory B cells from mice primed with one antigen could not suppress the activity of T cells primed with a second antigen 82 . Furthermore, the regulatory function of these B cells entirely depended on their ability to produce Il-10 (Ref. 82) . Together, these experiments showed that an antigen-specific Il-10-producing B cell subset can downregulate T cell activation.
In addition to suppressing T cell responses, cytokineproducing B cells can also enhance T cell mediated immune responses 48, 50, 80, [92] [93] [94] [95] . For example, in vitrogenerated effector B cells that produced either T H 1-or T H 2-type cytokines were shown to promote the in vitro activation and differentiation of naive T cells into effector T H 1 and T H 2 cells, respectively, through a cytokinedependent mechanism 80 . Similarly, Il-12-producing human B cells were shown to promote T H 1 cell differentiation in vitro 48, 92 , and Il-4-producing human B cells were reported to enhance T H 2 cell responses 95 . The findings from these in vitro experiments were recently replicated in mice, showing the importance of B cell cytokines in promoting T cell responses. In one set of experiments, TNF production by B cells was shown to be required for the generation of an optimal T H 1 cell response to Toxoplasma gondii 94 . In another set of experiments, the generation of a protective T H 2-type memory response to H. polygyrus was shown to depend on Il-2-producing B cells 50 . In summary, the current evidence suggests that B cells influence CD4 + T cell responses by several antibody-independent mechanisms. B cells can enhance T cell responses by presenting antigen and by providing co-stimulation; in addition, distinct populations of cytokine-producing B cells can have opposing roles and can either enhance or suppress T cell responses (fIG. 3) . [53] [54] [55] [77] [78] . Therefore B cell depletion might promote the development of a more tolerogenic environment in autoimmune disease through multiple mechanisms. First, the depletion of autoreactive effector B cells can block the B cell-T cell feedforward loop, preventing the further proliferation and reactivation of pathogenic T cells and thereby reducing organ-specific and systemic inflammation. Second, the decrease in inflammatory cytokine production favours the development and survival of regulatory T cells and regulatory B cells that can further dampen the autoimmune response. Finally, the transitional and naive B cells that initially repopulate the depleted host seem to express a distinct transcriptional profile and could be particularly effective in inducing or expanding regulatory T cell populations. Thus, B cell depletion therapy, when most effective, probably resets the balance between effector and regulatory populations of both B cells and T cells.
although we are making large strides in our understanding of the multifaceted roles of B cells in humoral and cellular immune responses, there is much that we still do not understand. The data convincingly show that B cells modulate T cell responses by presenting antigen, providing co-stimulation and secreting cytokines. Furthermore, it is becoming clear that the different effector functions of B cells are tightly controlled and that these tasks are carried out by functionally and phenotypically distinct effector and regulatory B cell subsets. What is less clear, however, is whether these functionally defined Be1, Be2 or regulatory B cells are actually distinct lineages or subsets. Furthermore, we do not know whether the antibody-independent effector functions are 'hard-wired' for certain B cells or whether B cells have the plasticity to change their effector functions depending on their local environment. In addition, is the development of an effector or regulatory phenotype an end fate decision for B cells, or can they enter the memory or plasma cell pools while maintaining some or all of their unique effector functions? Finally, we have yet to identify all of the in vivo signals that are required to trigger the development and activation of B cells with regulatory or effector functions. There are a large number of important questions remaining to be addressed; it is clear, however, that the scope of B cell biology has expanded beyond its initial boundaries of humoral immunity to encompass the wider field of CD4 + T cell immunity.
